8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Jan 31, 2017)

Filed January 31, 2017For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on January 31, 2017, to report its financial results for the fourth quarter and full year of 2016. The filing itself primarily serves as a notification of the release of this information via a press release, which is attached as an exhibit. Investors should refer to the press release (Exhibit 99) for the detailed financial performance and operational updates. While the 8-K does not contain the specific financial figures, it signals that Pfizer has disclosed its key performance indicators, revenue figures, earnings per share, and likely provided guidance or commentary on its outlook. This is a standard procedure for companies to ensure timely dissemination of material financial information to the public and is crucial for investors assessing the company's past performance and future prospects.

Key Highlights

  • 1Pfizer announced its Q4 and Full-Year 2016 financial results on January 31, 2017.
  • 2The 8-K filing primarily acts as a notification of the earnings release.
  • 3Detailed financial results and operational commentary are available in the press release furnished as Exhibit 99.
  • 4Investors should review the press release for specific financial data, including revenue, profit, and EPS.
  • 5The filing indicates the company is adhering to its regular reporting schedule.

Frequently Asked Questions

The specific financial results are detailed in the press release issued by Pfizer on January 31, 2017, which is included as Exhibit 99 in this 8-K filing. You should refer to Exhibit 99 for the full details.

This 8-K filing itself does not contain the specific financial metrics. It only announces that the results have been released. The detailed metrics such as revenue, net income, earnings per share (EPS), and any forward-looking guidance are found in the press release (Exhibit 99).

This 8-K filing is a report of past financial results. Any discussion of future guidance or outlook would be contained within the accompanying press release (Exhibit 99). Investors should carefully read the press release to determine if any new financial guidance was provided.

This 8-K filing is significant because it formally communicates that Pfizer has released its quarterly and annual financial performance. For investors, it's a trigger to review the detailed press release to understand the company's financial health, operational performance, and potential future trajectory.